Purpose: Compelling evidence has shown that pediatric brain tumor survivors are more susceptible to physical, neurocognitive, and psychological sequelae. This study assessed the impact of cancer and its treatment on the physical and psychological well-being, and quality of life of Hong Kong Chinese pediatric brain tumor survivors.
Methods: A total of 157 pediatric cancer survivors aged 8-16 were recruited. Of whom, 77 were pediatric brain tumor survivors and 80 were survivors of other cancers. Participants' depressive symptoms, level of self-esteem and quality of life were assessed. Additionally, 16 pediatric brain tumor survivors were randomly selected for a semi-structured interview.
Results: More than 70% pediatric brain tumor survivors presented significant number of depressive symptoms. Moreover, findings indicated that greater symptoms of depression in survivors were associated with lower level of self-esteem and quality of life. Qualitative interviews revealed that brain tumor and its treatment posed negative impact on the multiple domains of their daily life.
Conclusion: The findings of this study has addressed the literature gap by showing pediatric brain tumors have poorer psychological well-being, in terms of greater number of depressive symptoms, lower levels of self-esteem, and more severely compromised quality of life than survivors of other pediatric cancers. It is vital for healthcare professionals to develop and evaluate appropriate interventions with the aims to enhance the psychological well-being and quality of life among pediatric brain tumor survivors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejon.2019.06.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Amivantamab Plus Lazertinib in Patients With EGFR-mutant Non-small Cell Lung Cancer (NSCLC) After Progression on Osimertinib and Platinum-based Chemotherapy: Results From CHRYSALIS-2 Cohort A.
J Thorac Oncol
January 2025
Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address:
Introduction: Treatment options for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) with disease progression on/after osimertinib and platinum-based chemotherapy are limited.
Methods: CHRYSALIS-2 Cohort A evaluated amivantamab+lazertinib in patients with EGFR exon 19 deletion- or L858R-mutated NSCLC with disease progression on/after osimertinib and platinum-based chemotherapy. Primary endpoint was investigator-assessed objective response rate (ORR).
Evaluating the impact of performance status in elderly patients with glioblastoma.
J Clin Neurosci
January 2025
Department of Radiation Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA; Department of Neurosurgery, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA. Electronic address:
Background: Glioblastoma (GBM) is a common brain tumor with a poor prognosis. There is a paucity of knowledge regarding optimal treatment approaches for elderly patients with GBM who have a relatively good Karnofsky (KPS) or Eastern Cooperative Oncology Group (ECOG) performance status. This study compared treatment outcomes in older patients (≥65) with GBM based on their performance status, either high (KPS ≥ 70 and ECOG < 2) or low (KPS < 70 and ECOG ≥ 2), who underwent hypofractionated radiotherapy (HFRT) (40 Gy in 15 fractions) versus conventional fractionation (60 Gy in 30 fractions).
View Article and Find Full Text PDFResults of a patient-level pooled analysis of three studies of trastuzumab deruxtecan in HER2-positive breast cancer with active brain metastasis.
ESMO Open
January 2025
Dana-Farber Cancer Institute, Boston. Electronic address:
Background: Brain metastases (BMs) are common in human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer, increasing morbidity and mortality. Systemic therapy for BMs can be effective, with the triple combination of trastuzumab, capecitabine, and tucatinib being a potential standard. More recently, intracranial activity of antibody-drug conjugates has been reported, but the size of individual studies has been small.
View Article and Find Full Text PDFSingle-cell multi-omics reveals tumor microenvironment factors underlying poor immunotherapy responses in ALK-positive lung cancer.
Cancer Commun (Lond)
January 2025
Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul, Republic of Korea.
Hierarchically Engineered Self-Adaptive Nanoplatform Guided Intuitive and Precision Interventions for Deep-Seated Glioblastoma.
ACS Nano
January 2025
Shanghai Frontiers Science Center of Drug Target Identification and Delivery, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China.
Glioblastoma multiforme (GBM), particularly the deep-seated tumor where surgical removal is not feasible, poses great challenges for clinical treatments due to complicated biological barriers and the risk of damaging healthy brain tissue. Here, we hierarchically engineer a self-adaptive nanoplatform (SAN) that overcomes delivery barriers by dynamically adjusting its structure, surface charge, particle size, and targeting moieties to precisely distinguish between tumor and parenchyma cells. We further devise a AN-uided ntuitive and recision ntervention (SGIPi) strategy which obviates the need for sophisticated facilities, skilled operations, and real-time magnetic resonance imaging (MRI) guidance required by current MRI-guided laser or ultrasound interventions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!